Nasdaq grts.

Aug 9, 2023 · Second Quarter 2023 Financial Results. Cash, cash equivalents, marketable securities and restricted cash were $122.3 million as of June 30, 2023, compared to $185.2 million as of December 31, 2022 ... The 36-month beta value for GRTS is also noteworthy at 0.44. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”. The average price estimated by analysts for GRTS is $10.40, which is $9.08 above than the current price.Find the latest Institutional Holdings data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com. Nov 14, 2023 · Gritstone Bio Inc (NASDAQ:GRTS) trade information. Sporting -3.50% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 11/13/23 when the GRTS stock price touched $1.38 or saw a rise of 25.61%. Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

Aug 1, 2023 · Financials. GRTS has a market cap of $169mn and a cash balance of $153mn. Research and development expenses were $30.5 million for the three months ended March 31, 2023 while general and ... EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...

Jan 13, 2022 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Mar 10, 2022 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

EMERYVILLE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...A. Gritstone Bio ( GRTS) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $1.6M, which ... Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.The stock price for Gritstone Bio ( NASDAQ: GRTS) is $ 1.31 last updated Today at November 27, 2023, 10:46 AM PST. Q.WebThe average trading volume of GRTS on November 15, 2023 was 2.18M shares. GRTS) stock’s latest price update. Gritstone Bio Inc (NASDAQ: GRTS)’s stock price has gone rise by 8.72 in comparison to its previous close of 1.37, however, the company has experienced a -11.86% decrease in its stock price over the last five trading days.

GRCL. Gracell Biotechnologies Inc. 5.05. -0.25. -4.72%. In this piece, we will take a look at the 12 Best Stocks For Day Trading. If you want to skip our introduction to trading indicators and the ...

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its ...

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Gritstone bio's $785 million collaboration for HIV therapies has quantified the value of EDGE more than any Wall Street analyst could ever do. Gilead has already given GRTS $30 million upfront and ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.According to the issued ratings of 4 analysts in the last year, the consensus rating for Gritstone bio stock is Buy based on the current 4 buy ratings for GRTS. The average twelve-month price prediction for Gritstone bio is $7.33 with a high price target of $8.00 and a low price target of $7.00. Learn more on GRTS's analyst rating history.Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train ...

EMERYVILLE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Follow. EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...A. Gritstone Bio ( GRTS) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $1.6M, which ... Eric Enderson. November 21, 2023. In the last trading session, 1.28 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.47. With the company’s per share price at $1.32 changed hands at -$0.04 or -2.94% during last session, the market valuation stood at $125.85M. GRTS’s last price was a discount ...Sep 16, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone ...

EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced... -- 10,000 participant randomized Phase 2b study will evaluate Gritstone s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus ... (Nasdaq: GRTS), and has served as its President, Chief Executive Officer, and board member since its inception in August 2015. Prior to Gritstone, in April ...

Gritstone bio, Inc. Common Stock (GRTS) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.WebHere's Why We're Not Too Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Situation May 26. Consensus revenue estimates increase to US$46.1m May 13. First quarter 2021 earnings released: EPS US$0.10 (vs US$0.71 loss in 1Q 2020) May 07. Gritstone Oncology EPS beats by $0.41, beats on revenue(Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that Andrew ...The largest stake in Gritstone Oncology, Inc. (NASDAQ:GRTS) was held by Redmile Group, which reported holding $26.8 million worth of stock at the end of September.It was followed by Casdin Capital ...Gritstone Bio Inc (NASDAQ:GRTS) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% ...EMERYVILLE, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Gritstone bio, Inc. Common Stock (GRTS) Pre-Market Stock Quotes - Nasdaq offers ...Verizon, Walgreens, and 4 Other Stocks. The S&P 500's Best Payouts: 7%+ Dividend Yields. Get the latest GRTS (GRTS) real-time quote, historical performance, charts, and other financial...

Dec 4, 2023 · Gritstone Bio Inc (NASDAQ: GRTS)’s stock price has soared by 17.69 in relation to previous closing price of 1.30. Nevertheless, the company has seen a gain of 11.68% in its stock price over the last five trading days. Zacks Investment Research reported 2023-10-16 that Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy ...

EMERYVILLE, Calif., VANCOUVER, British Columbia, and BASEL, Switzerland, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to ...

GRTS: Get the latest Gritstone Oncology stock price and detailed information including GRTS news, historical charts and realtime prices. Indices Commodities Currencies StocksGritstone bio, Inc. (NASDAQ:GRTS) is an American healthcare company that develops treatments for cancer and other diseases. It is another highly rated stock on our list since the average rating is ...Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...As published in their initiating research note from Evercore ISI on March 31, 2023, Gritstone Bio Inc [GRTS] has been an Outperform. Analyzing GRTS Stock Performance. On Wednesday, Gritstone Bio Inc [NASDAQ: GRTS] plunged -7.65% to $1.69. The stock’s lowest price that day was $1.66, but it reached a high of $1.82 in the …Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its ...EMERYVILLE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS ), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase 2b comparative study ...Nov 17, 2023 · Gritstone Bio Inc (NASDAQ:GRTS) showed a performance of -33.50% in past 30-days. Number of shares sold short was 9.12 million shares which calculate 2.48 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $10.40 to the stock, which implies a rise of 86.83% to its current value. EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...EMERYVILLE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the... GRTS : 2.59 (-2.63%) Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 4, 2022 Globe Newswire - Thu Jul 21, 2022.EMERYVILLE, Calif., VANCOUVER, British Columbia, and BASEL, Switzerland, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to ...Verizon, Walgreens, and 4 Other Stocks. The S&P 500's Best Payouts: 7%+ Dividend Yields. Get the latest GRTS (GRTS) real-time quote, historical performance, charts, and other financial...

EMERYVILLE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...9 มี.ค. 2566 ... (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today reported financial results ...Gritstone bio (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Track Gritstone Bio Inc (GRTS) Stock Price, Quote, latest community messages, chart, news and other stock related information.Instagram:https://instagram. where to paper trade optionsarmour reitpurchase wwe stockpds biotechnology stock Find the latest Earnings Report Date for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com. dividend ex dates calendarpepperstone broker usa Gritstone bio ( NASDAQ: GRTS) uses its vaccine technology to promote an immune response against a patients cancer or to prevent or treat infectious disease. In late September, 2023, GRTS announced ... best funds to invest in fidelity The 36-month beta value for GRTS is also noteworthy at 0.44. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”. The average price estimated by analysts for GRTS is $10.40, which is $9.08 above than the current price.marketbeat.com - July 5 at 5:00 AM. Gritstone bio (NASDAQ:GRTS) shareholders have endured a 70% loss from investing in the stock three years ago. finance.yahoo.com - July 4 at 10:02 AM. Board Member at Gritstone Bio Acquires Company Stock Options Worth 51,800 Shares. benzinga.com - June 22 at 11:42 PM.